COVID-19 Viral Reactivation Linked to Long‑COVID Disability, Study Shows

COVID-19 viral reactivation triggers dormant pathogens

A recent Reuters‑covered study followed 1,154 hospitalized patients for a year, uncovering that severe infection can rouse latent viruses even in immunocompetent individuals. Researchers detected reactivation of EBV, CMV, HSV and the often‑overlooked anelloviruses, with nearly ↓ 48% of participants showing at least one viral flare during the acute phase. Long‑COVID sufferers who continued to feel fatigue, reduced mobility and brain fog were significantly more likely to retain active anelloviruses, a correlation that rose to ↑ 30% among those with persistent disability.

“If these findings are validated, the urgency to develop antivirals for reactivated viruses will sky‑rocket,” said Dr. Esther Melamed, co‑author of the paper.

The team collected blood, nasal swabs and, for ventilated patients, lung fluid at six intervals in the first month, then at three, six, nine and twelve months. Each virus displayed its own reactivation timeline—EBV and anelloviruses surged early, while CMV and HSV peaked later—accompanied by distinct immune and metabolic shifts. The phenomenon mirrors earlier observations in astronauts and Antarctic researchers, where extreme stress provoked herpesvirus shedding despite robust health. Scientists propose that systemic inflammation, driven by cytokines like IL‑1 and IL‑6, temporarily loosens immune surveillance, allowing latent viruses to resume replication. While the study establishes a compelling correlation, causality remains unproven; prospective trials with antiviral agents are the next logical step. For broader context on how the pandemic reshapes disease patterns, see our ongoing analysis.

Intel provided by Elena Rostova (Socio-Economic Trends Analyst).